4//SEC Filing
WELCH DAVID E 4
Accession 0001079973-09-000088
CIK 0001167419other
Filed
Jan 27, 7:00 PM ET
Accepted
Jan 28, 7:41 PM ET
Size
13.0 KB
Accession
0001079973-09-000088
Insider Transaction Report
Form 4
WELCH DAVID E
Director
Transactions
- Award
Stock Options
2009-01-27+50,000→ 50,000 totalExercise: $1.33From: 2009-01-27Exp: 2019-01-27→ Common Stock (50,000 underlying)
Holdings
- 50,000
Stock Options
Exercise: $1.60From: 2006-04-18Exp: 2016-04-18→ Common Stock (50,000 underlying) - 100,000
Stock Options
Exercise: $0.76From: 2004-10-01Exp: 2014-10-01→ Common Stock (100,000 underlying) - 50,000
Stock Options
Exercise: $0.80From: 2005-03-28Exp: 2015-03-28→ Common Stock (50,000 underlying) - 50,000
Stock Options
Exercise: $6.63From: 2008-01-17Exp: 2018-01-17→ Common Stock (50,000 underlying) - 50,000
Stock Options
Exercise: $2.96From: 2007-01-24Exp: 2017-01-24→ Common Stock (50,000 underlying)
Footnotes (5)
- [F1]Options vest over three years, at the rate of 33.3% at the end of year one, 66.7% at the end of year two, and 100% at the end of year three.
- [F2]Options vest over three years, at the rate of 33.3% on 4/18/2006, 66.7% on 4/18/2007, and 100% on 4/18/2008. This stock option grant is exempt from Section 16(b) pursuant to Rule 16b-3(d).
- [F3]Options were granted pursuant to Board approval on January 24, 2007. The aggregate number of stock options granted was 50,000. One-third (16,666) of the options vest each year for three years following the date of grant. This transaction is exempt from Section 16(b) pursuant to Rule 16b-3(d).
- [F4]Options were granted pursuant to Board approval on January 17, 2008. The aggregate number of stock options granted was 50,000. One third (16,666) of the options vest each year for three years following the date of grant. This transaction is exempt from Section 16(b) pursuant to Rule 16b-3(d).
- [F5]Options were granted pursuant to Board approval on January 27, 2009. The aggregate number of stock options granted was 50,000. One third (16,666) of the options vest each year for three years following the date of grant. This transaction is exempt from Section 16(b) pursuant to Rule 16b-3(d).
Documents
Issuer
AspenBio Pharma, Inc.
CIK 0001167419
Entity typeother
Related Parties
1- filerCIK 0001221298
Filing Metadata
- Form type
- 4
- Filed
- Jan 27, 7:00 PM ET
- Accepted
- Jan 28, 7:41 PM ET
- Size
- 13.0 KB